ライフサイエンスコーパス: topical steroid

1 ntraocular inflammation that resolved with a topical steroid.

2 ination with immunomodulatory agents such as topical steroids.

3 ut costs regularly when making choices about topical steroids.

4 pants treated with longer-term (6-60 months) topical steroids.

5 D participants who filled prescriptions for topical steroids.

6 therapies and were generally manageable with topical steroids.

7 oNV that had not responded to treatment with topical steroids.

8 dietary restriction and those that received topical steroids.

9 pical antibiotics, and 98% were treated with topical steroids.

10 dalities or have undesired side effects from topical steroids.

11 nflammatory drugs are minimizing the role of topical steroids.

12 ociated pruritus, and inadequate response to topical steroids.

13 oral steroids 1.5 (1.0-2.4), "super potent" topical steroids 1.2 (0.8-1.8) , "low potency" topical s

14 und-associated group were more likely to use topical steroids (20/22 [91%] vs 17/27 [63%]; P = 0.024)

15 ng with topical and systemic antibiotics and topical steroids (221 children), and one to no specific

16 olved following both dietary restriction and topical steroids (3/17 and 5/9 patients respectively, P

17 prescribed drug class by volume, followed by topical steroids (86%) and nonsteroidal anti-inflammator

18 Treatment included topical steroids (93%), with 1% supplemented by oral ste

19 Neither an antibiotic nor a topical steroid alone or in combination was effective as

20 with adjunctive CXL and topical steroids vs topical steroids alone (0.04; 95% CI, -0.09 to 0.17; P =

21 s best treated with an initial slow taper of topical steroids; although adjuvant systemic anti-inflam

22 ticipants were treated with a combination of topical steroids and antibiotics postoperatively, applie

23 He was treated with topical steroids and antibiotics, methylprednisolone pul

24 oncurrent bacterial keratitis who were using topical steroids and antiviral and antifungal drugs befo

25 Topical steroids and atropine were started.

26 rneal findings, resolution was achieved with topical steroids and lubrication, whereas some patients

27 ll patients had failed previous therapy with topical steroids and methotrexate and/or cyclosporine.

28 Inflammation resolved with topical steroids and non-steroidal anti-inflammatory dru

29 ers completely resolved after treatment with topical steroids and oral doxycycline.

30 Topical steroids and oral nonsteroidal anti-inflammatory

31 Mild scleritis/limbitis responsive to topical steroids and oral NSAIDs was present in 11 of 36

32 Most patients with severe BKC require both topical steroids and systemic antibiotics to control dis

33 opical antibiotics, oral acyclovir, low-dose topical steroids and systemic steroids were started.

34 lgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most

35 All patients were managed with frequent topical steroids and were followed closely for signs of

36 kept under observation, with the addition of topical steroids and/or cycloplegics in eyes that demons

37 ps requiring an escalation in treatment with topical steroids and/or systemic antibiotics, and 75% of

38 ncluded use of skin moisturizers, sunscreen, topical steroid, and doxycycline.

39 , including topical prostaglandin analogues, topical steroids, and argon laser trabeculoplasty.

40 shed new light on the mechanism of action of topical steroids, and demonstrates the critical role of

41 Medicare and patient out-of-pocket costs for topical steroids, and to model potential savings that co

42 ance of food antigens; broad applications of topical steroids; and, eventually, pathway-specific biol

43 efficacy and safety of standard versus soft topical steroid application after cataract surgery.

44 .0% to 1.0%); 35.7% vs. 39.0% reported using topical steroids (aRD -3.3, 95% CI -9.2 to 2.7); and 7.3

45 Although topical steroids are among the most commonly prescribed

46 Topical steroids are frequently used to control corneal

47 ding sound advice and easing fears regarding topical steroids, as well as pursuing conservative treat

48 Medicare Part D expenditures on topical steroids between 2011 and 2015 were $2.3 billion

49 es in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches,

50 istence of AD severity and responsiveness to topical steroids, calcineurin inhibitors and step-up tre

51 Dietary restriction alone, similar to topical steroids, can reverse fibrosis in children with

52 Although topical steroids continue to be a mainstay of therapy, n

53 discharge, which were promptly resolved with topical steroid cream and eye drops.

54 The most common first-line treatments were topical steroid drops (372 [30%]), topical nonsteroidal

55 Clinical symptoms of epiphora settled with topical steroid drops, but the clinical signs of chronic

56 Apart from the topical steroids during the first week, medical treatmen

57 reatments consist of proton pump inhibitors, topical steroids, elemental diet, and empirical food eli

58 se a system to allow the substitution of one topical steroid for another of the same class and vehicl

59 ives on a system to automatically substitute topical steroid for cheaper alternatives of the same cla

60 reated with very strong or strongest potency topical steroids for 3-9 years.

61 First-line therapies are topical steroids for inflammatory causes, such as hydroc

62 To compare standard and frequent topical steroids for postsurgical macular edema (ME).

63 oral suspension (BOS), a novel muco-adherent topical steroid formulation, to reduce symptoms and esop

64 substitution of the most affordable generic topical steroid from the corresponding potency class may

65 uld result from substitution of the cheapest topical steroid from the corresponding potency class.

66 Rising costs of topical steroids have increased overall health care and

67 In addition, there is limited evidence that topical steroids improve the sense of smell, especially

68 ases in a mean of 6.1 months via tapering of topical steroids in 15 (46.9%) of patients.

69 lograft rejection successfully reversed with topical steroids in 2 eyes (9%), secondary graft failure

70 Uveitis responded to topical steroids in all cases.

71 erved in 6 eyes (7.5%) and was reversed with topical steroids in all cases.

72 that topical NSAIDs are more effective than topical steroids in preventing PCME.

73 any DSEK patients are maintained on low-dose topical steroids indefinitely.

74 maintaining adequate amebicidal therapy if a topical steroid is used in the management of Acanthamoeb

75 be reasonably supported, whereas the use of topical steroids is unlikely to be beneficial.

76 Potent topical steroids, Janus kinase inhibitors and tacrolimus

77 Anti-inflammatory drugs such as topical steroids may be beneficial but are underresearch

78 Topical steroids might reduce stomatitis incidence and s

79 e 2% (high confidence) and least common with topical steroids (moderate confidence).

80 ve systemic antibiotics (n = 23 [69.7%]) and topical steroids (n = 29 [87.9%]), although specific med

81 have the potential to reduce the quantity of topical steroids necessary to keep disease quiescent.

82 etween patients treated postoperatively with topical steroids, nonsteroidal anti-inflammatory medicat

83 Treatment requires moderately potent topical steroid ointments.

84 pical steroids were compared to those taking topical steroids only.

85 pical steroids 1.2 (0.8-1.8) , "low potency" topical steroids OR 1.1 (0.7-1.6); pimecrolimus 0.8(0.4-

86 Treatment is based on systemic or topical steroids or identification and elimination of fo

87 d, and AEs resolved in 4 of 5 patients after topical steroids or observation.

88 ns comprise skin-directed therapies, such as topical steroids or phototherapy, and systemic therapies

89 defined as no disease activity and no use of topical steroids or systemic antibiotic treatment.

90 ths), with either exclusive slow tapering of topical steroids or the need for systemic immunosuppress

91 Anecdotal use of topical steroid oral prophylaxis has been reported in pa

92 rs between patients by treatment response to topical steroids (oral viscous budesonide), thus offerin

93 Patients' out-of-pocket spending for topical steroids over the same period was $333.7 million

94 resolution of inflammation, with or without topical steroids, over the course of a few months.

95 tacrolimus OR 0.8 (0.4-1.7), and concomitant topical steroids, pimecrolimus, and tacrolimus 1.0 (0.3-

96 IOL at the time of surgery and received only topical steroids postoperatively.

97 was not increased with short-term use of any topical steroid potency (low confidence) but skin thinni

98 nt therapies include proton pump inhibitors; topical steroid preparations, such as fluticasone and bu

99 Most topical steroids prescribed were generic drugs.

100 of breakthrough inflammation than a standard topical steroid regimen with no significant differences

101 uencing dermatologist decision-making around topical steroid selection, outcomes of unaffordable medi

102 ive therapies, most commonly due to fears of topical steroid side-effects and dissatisfaction with co

103 ry outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% a

104 se in Medicare and out-of-pocket spending on topical steroids that is driven by higher costs for gene

105 Concerning topical steroids, the most frequently instructed item wa

106 With topical steroid therapy 5 times per day during the first

107 e may be treated effectively with aggressive topical steroid therapy and lubrication.

108 Early intensified postoperative topical steroid therapy constitutes an effective prophyl

109 proliferation in the pancreatic LN, although topical steroid therapy did not enhance this.

110 ill patients; use of genetic techniques and topical steroid therapy in treating graft-versus-host di

111 With hourly topical steroid therapy none of the patients developed C

112 Patients with CoNV unresponsive to topical steroid therapy.

113 om 12 patients (23%) had previous failure to topical steroid therapy.

114 ival injection, or hypopyon, and responds to topical steroid therapy.

115 dle (MN) delivery system and combine it with topical steroid to minimise local inflammation and promo

116 of whether a child's AD required the use of topical steroids, topical calcineurin inhibitors, or oth

117 An effective topical steroid treatment in EoE patients is important.

118 y significant aqueous-deficient dry eye when topical steroid treatment is deemed appropriate.

119 All patients required topical steroid treatment, 3 required amniotic membrane

120 l recurrences, especially after cessation of topical steroid treatment, and in individuals with ident

121 Following cessation of topical steroid treatment, recurrence occurred after a m

122 hes after cataract surgery and postoperative topical steroid treatment.

123 Topical steroid treatments for eosinophilic esophagitis

124 wer adverse-effect profile than conventional topical steroid treatments or other medical or surgical

125 bination of proton-pump inhibitors (PPI) and topical steroids (TS) is used to treat children with eos

126 Topical steroid use (37/49 [76%]) was the most common as

127 es (HR 3.44, 95% CI 1.69-6.99, P < .01), and topical steroid use (HR 2.74, 95% CI 1.33-5.62, P < .01)

128 idal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsificat

129 Topical vancomycin use, topical steroid use, and contact lens wear did not incre

130 1%) underwent cataract extraction related to topical steroid use.

131 no difference in 6-month VA with adjunctive topical steroids vs placebo (-0.04; 95% CI, -0.18 to 0.0

132 to 0.09; P = .58) or with adjunctive CXL and topical steroids vs topical steroids alone (0.04; 95% CI

133 Increasing frequency of use of swallowed topical steroids was associated with a lower risk for bo

134 ssociated with graft rejection, cessation of topical steroids was most significant.

135 tion of topical NSAIDs filled in addition to topical steroids were compared to those taking topical s

136 Topical steroids were initiated in the first month of pr

137 scarring and visual debilitation by the time topical steroids were initiated, and his final corrected

138 avoid mis-diagnosis and over-treatment with topical steroids which in turn may increase intraocular

139 The patients were started on oral and topical steroids which led to resolution of hypopyon uve

140 trials published from 1996 onward comparing topical steroids with topical NSAIDs in controlling infl

141 Topical steroid withdrawal (TSW) is a controversial diag

142 nt savings from substitution of the cheapest topical steroid within the corresponding potency class w